Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | MMP3 | P08254 | 1/20 | 0.43 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.40 |
| ▸ | USP7 | Q93009 | 3/20 | 0.40 |
| ▸ | PREP | P48147 | 2/20 | 0.40 |
| ▸ | SENP1 | Q9P0U3 | 2/20 | 0.40 |
| ▸ | CELA1 | Q9UNI1 | 1/20 | 0.40 |
| ▸ | FYN | P06241 | 1/20 | 0.39 |
| ▸ | PEPD | P12955 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 4/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | MGAM | O43451 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | SI | P14410 | 1/20 | 0.38 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.38 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.36 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7064896 | 0.86 | ESR1 (0.43) | HSD17B10MMP2MMP3PREPSENP1 | |
| SCHEMBL2114962 | 0.80 | BCAT2 (0.52) | HSD17B10MMP2MMP3BCAT2USP7 | |
| SCHEMBL1892489 | 0.78 | HNF4A (0.55) | HSD17B10MMP2MMP3BCAT2FYN | |
| SCHEMBL3805560 | 0.77 | USP7 (0.48) | HSD17B10MMP2MMP3BCAT2USP7 | |
| SCHEMBL3661535 | 0.77 | BCAT2 (0.42) | HSD17B10BCAT2KEAP1NFE2L2 | |
| SCHEMBL29438199 | 0.77 | BCAT2 (0.42) | HSD17B10BCAT2KEAP1NFE2L2 | |
| SCHEMBL15779321 | 0.77 | HSD17B10 (0.53) | HSD17B10MMP2MMP3BCAT2USP7 | |
| SCHEMBL4750554 | 0.76 | DGAT1 (0.41) | HSD17B10MMP2MMP3PREPSENP1 | |
| SCHEMBL27707211 | 0.75 | SENP1 (0.46) | MMP2MMP3USP7PREPSENP1 | |
| SCHEMBL28308128 | 0.75 | PREP (0.38) | USP7PREPSENP1CELA1ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102702013-B | Nuclear receptor binding agents | GTX INC. (US) | 2016-02-10 | — | — | CN | claimed |
| US-20160031797-A1 | ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF | GTX, INC. | 2016-02-04 | — | — | US | claimed |
| WO-2008130571-A1 | NUCLEAR RECEPTOR BINDING AGENTS | GTX, INC. (US) | 2008-10-30 | — | — | WO | claimed |
| US-20070265296-A1 | Nuclear receptor binding agents | GTX, INC. | 2007-11-15 | — | — | US | claimed |
| US-9409856-B2 | Estrogen receptor ligands and methods of use thereof | GTX, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| CN-102702013-B | Nuclear receptor binding agents | GTX INC. (US) | 2016-02-10 | — | — | CN | disclosed |
| US-20160031797-A1 | ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF | GTX, INC. | 2016-02-04 | — | — | US | disclosed |
| CN-102351732-B | Nuclear receptor binding agents | GTX INC. (US) | 2014-10-29 | — | — | CN | disclosed |
| US-8637706-B2 | Nuclear receptor binding agents | GTX, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20120157539-A1 | NUCLEAR RECEPTOR BINDING AGENTS | GTX, INC. | 2012-06-21 | — | — | US | disclosed |
| EP-2455362-A1 | Nuclear receptor binding agents | GTX, Inc. (US) | 2012-05-23 | — | — | EP | disclosed |
| US-8158828-B2 | Nuclear receptor binding agents | GTX, INC. (US) | 2012-04-17 | — | — | US | disclosed |
| US-20090062341-A1 | Nuclear receptor binding agents | GTX, INC | 2009-03-05 | — | — | US | disclosed |
| WO-2008130571-A1 | NUCLEAR RECEPTOR BINDING AGENTS | GTX, INC. (US) | 2008-10-30 | — | — | WO | disclosed |
| US-20070265296-A1 | Nuclear receptor binding agents | GTX, INC. | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031797-A1 | ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF | ESRRB, ESRRA, ESR2 | HSD17B10 331/4885MMP2 3247/4885MMP3 2415/4885 |
| US-20070265296-A1 | Nuclear receptor binding agents | GPER1, ESRRG, ESR2 | HSD17B10 639/4885MMP2 4442/4885MMP3 2884/4885 |
| US-20090062341-A1 | Nuclear receptor binding agents | GPER1, ESRRG, ESR2 | HSD17B10 639/4885MMP2 4442/4885MMP3 2884/4885 |
| US-20120157539-A1 | NUCLEAR RECEPTOR BINDING AGENTS | GPER1, ESRRG, ESR2 | HSD17B10 639/4885MMP2 4442/4885MMP3 2884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.